Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Askew

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The American Journal of Pathology|March 23, 2025
The Microbial Metabolite δ-Valerobetaine Strengthens the Gut Epithelial BarrierLauren C Askew, C Anthony Gacasan, Maria E Barbian, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backboneDavid B Whitman, Ben C Askew, Le T Duong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
Circulation|August 5, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injuryJ J Cook, J D Glass, G R Sitko, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2010
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonistsQingyian Liu, Wenyuan Qian, Aiwen Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1996
Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studiesT Prueksaritanont, L M Gorham, J D Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptorsM S Egbertson, B Bednar, B C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
Bioorganic & Medicinal Chemistry Letters|August 19, 2008
Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic painKaustav Biswas, Toshihiro Aya, Wenyuan Qian, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2006
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin coreChristopher Fotsch, Gloria Biddlecome, Kaustav Biswas, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The American Journal of Pathology|March 23, 2025
The Microbial Metabolite δ-Valerobetaine Strengthens the Gut Epithelial BarrierLauren C Askew, C Anthony Gacasan, Maria E Barbian, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backboneDavid B Whitman, Ben C Askew, Le T Duong, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
Circulation|August 5, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injuryJ J Cook, J D Glass, G R Sitko, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2010
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonistsQingyian Liu, Wenyuan Qian, Aiwen Li, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1996
Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studiesT Prueksaritanont, L M Gorham, J D Ellis, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptorsM S Egbertson, B Bednar, B C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.
Bioorganic & Medicinal Chemistry Letters|August 19, 2008
Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic painKaustav Biswas, Toshihiro Aya, Wenyuan Qian, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2006
A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin coreChristopher Fotsch, Gloria Biddlecome, Kaustav Biswas, et al.
Pageof 4